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SHORT REPORT ABSTRACT: Noninvasive ventilation (NIV) appears to improve survival
and quality of life in patients with amyotrophic lateral sclerosis (ALS), but
little is known about predictors of NIV tolerance. NIV use was assessed and
clinical predictors of tolerance were investigated, using predictive modeling,
in ALS patients diagnosed and followed in our clinic until death over a 4-year
time period. Patients were prescribed NIV based on current practice param-
eters when respiratory symptoms were present or forced vital capacity was
less than 50%. We prescribed NIV in 52% (72) of patients. For those
prescribed NIV, information regarding tolerance was available for 50 pa-
tients, with 72% (36) tolerant to its use. Tolerance was six times more likely
in limb-onset than bulbar-onset ALS patients, with a trend toward reduced
tolerance in those with lower forced vital capacity at NIV initiation. Age,
gender, and duration of disease were not predictors of NIV tolerance. We
conclude that a majority of ALS patients who are prescribed NIV can
successfully become tolerant to its use.
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Amyotrophic lateral sclerosis (ALS) is clinically heter-
ogeneous in presentation and progression of symp-
toms, with respiratory failure as the most common
cause of death.11 Location of symptom onset (bulbar
rather than limb) and rapid rate of respiratory decline
are associated with shorter survival.10,14 Survival ap-
pears to be extended, and quality of life improved,
through the use of noninvasive ventilation (NIV) for at
least 4 hours per night.2,4,12 Given the significant ben-
efits NIV provides, its use has become the standard of
care,17 but only half of ALS patients are able to tolerate
NIV to achieve these benefits.1,12 Additionally, some
studies have shown that ALS patients with more bulbar
symptoms are less likely to tolerate NIV,1,4 whereas
others report no difference in tolerability between bul-
bar-onset and limb-onset ALS.12 The purpose of the
present study was to determine whether initial clinical
features and pulmonary function tests are useful in
predicting NIV tolerance among ALS patients, using a
multivariable approach. Our study provides further in-
formation on factors associated with tolerance while
adjusting for important confounders. These data will
be helpful in clinical practice to identify those patients
with the highest likelihood of being intolerant, and
may also help to identify subgroups of patients in
whom tolerability issues deserve further study.
METHODS
Patients. We included patients diagnosed with def-
inite or probable ALS6 who were followed in our
institutional ALS clinic until death between 2000
and 2003. Patients were seen every 3 months and
prescribed bilevel positive airway pressure (BiPAP)
when respiratory symptoms were present and either
forced vital capacity (FVC) was 50%17 or mean
inspiratory pressure (MIP) was 60 cm H2O.3 We
did not start NIV until sialorrhea was effectively con-
trolled. For sialorrhea, we used glycopyrrolate or
transdermal hyoscine or, if pseudobulbar symptoms
were present, amitriptyline. If patients failed or had
a contraindication to pharmacologic treatment, they
received botulinum toxin injections into the salivary
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glands.8 Pressures were begun at 8 cm H2O inspira-
tory positive airway pressure (IPAP) and 3 cm H2O
expiratory positive airway pressure (EPAP),15,16 using
heated humidification and NasalAire interfaces to
minimize nasal congestion and claustrophobia from
large masks, respectively.15 If nasal congestion con-
tinued, intranasal steroid sprays were prescribed. Pa-
tients were contacted after 1 week by telephone to
determine whether respiratory symptoms had im-
proved. If patients continued to have respiratory
symptoms, the inspiratory positive airway pressure
was increased by 2 cm H2O increments weekly until
symptoms improved.15 The study was approved by
the local institutional review board with a waiver of
informed consent.
Clinical Classification. A retrospective chart review
was conducted in order to collect information on the
dates of ALS symptom onset, diagnosis, NIV initia-
tion, and death, in addition to age at symptom onset,
gender, smoking status at diagnosis, site of symptom
onset, FVC at diagnosis, and FVC at the time of NIV
initiation. Patients were classified as tolerant to NIV
if they used it nightly for 4 hours as documented at
each clinic visit.
Statistical Methods. Proportions and means with
standard deviations were calculated for demo-
graphic variables and baseline patient characteris-
tics. A chi-square test was performed to assess the
relationship between gender or site of symptom on-
set and prescription of NIV. The relationship be-
tween tolerance and baseline variables was assessed
using a chi-square test for dichotomous variables and
Wilcoxon’s rank sum test for continuous variables.
No adjustment for multiple comparisons was made.
The relationship between FVC (dichotomized: low
80%, high 80%) and location was also assessed
using a chi-square test. Univariable logistic regres-
sion was used to assess the relationship between NIV
tolerance and the following variables: age; time from
symptom onset to NIV initiation; symptom onset
location (bulbar vs. limb); gender; and FVC at the
time of NIV initiation. A multivariable logistic regres-
sion model was then fit with these five explanatory
variables. Predictors were selected in a prespecified
fashion based on their biologically plausible relation-
ship with the outcome. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated for each
variable in the models. Internal model validation was
performed with bootstrapping (200 times with re-
placement).9 The overall model performance was
assessed by calculating the C value. S-Plus 6.1 soft-
ware (Insightful Corp., Seattle, Washington, 2002)
was used for the analyses.
RESULTS
Clinical Findings. There were 139 patients with ALS
who fulfilled selection criteria. Baseline characteris-
tics are shown in Table 1. Overall, 72 (52%) were
prescribed NIV. There were no differences in pre-
scription of NIV by gender (P  0.44) or site of
symptom onset (P  0.58). Of those patients who
were prescribed NIV, information on tolerance was
available for 50 (70%). Of those 22 for whom toler-
ance could not be determined, the reason was as
follows: 18 did not survive long enough for a deter-
mination to be made; 2 were lost to follow-up; and 2
had inadequate chart documentation. Thirty-six
(72%) were tolerant to NIV, and 14 (28%) were not.
Comparison of baseline variables for tolerant and
nontolerant patients is shown in Table 1. Patients
who were tolerant were more likely to have limb-
onset symptoms and have higher FVCs at NIV initi-
ation.
Table 1. Demographics and baseline clinical characteristics.
Overall
Tolerant (n  36),
mean (SD)





Age 139 62.6 (12.1) 63.2 (12.3) 62.8 (11.4) 0.97
Female (%) 139 48 50 36 0.36
BMI 92 25.8 (7.1) 27.1 (7.8) 25 (4.3) 0.88
Limb onset (%) 139 63 67 29 0.01
FVC at NIV start 63 46.7 (11.8) 49.6 (10.9) 42 (12.0) 0.04
PFTs met for NIV (%) 139 83 97 93 0.48
Symptom onset to PFT
criteria met (days) 115 738 (689.4) 800 (793.3) 694.9 (577.9) 0.51
Diagnosis to NIV (days) 72 341 (435.6) 293.8 (349.8) 378.4 (370.2) 0.71
Diagnosis to death (days) 139 671 (632.2) 701 (449.5) 946.1 (822.4) 0.63
BMI, body mass index; FVC, forced vital capacity (percent predicted); PFT, pulmonary function test; NIV, noninvasive ventilation.
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There were 119 patients with a documented FVC
within 3 months of diagnosis. Of these patients, 84
(71%) had FVC  80%. Of those with FVC  80%,
8 (23%) had bulbar-onset and 27 (77%) had limb-
onset symptoms. Of those with FVC  80%, 33
(39%) had bulbar-onset and 51 (61%) had limb-
onset symptoms. There was no difference in the
proportion of bulbar-onset and limb-onset in those
with high or low FVCs (P  0.09).
Predictors of NIV Tolerance. In the univariable anal-
yses, limb-onset disease was associated with NIV tol-
erance [OR  5 (95% CI: 1.30, 20.0)]. FVC at NIV
start time was not significantly associated with NIV
tolerance [OR  2.9 (95% CI: 0.96, 8.64)], despite
an evident trend. Age [OR  1.36 (0.43, 4.33)],
female gender [OR  1.80 (0.50, 6.43)], and time
from symptom onset to NIV initiation [OR  1.24
(0.65, 2.38)] were not associated with NIV tolerance
in the univariable models.
In the multivariable model, only limb onset was
independently associated with NIV tolerance [OR 
6.25 (1.09, 33.33)]. No other predictive variable was
associated with NIV tolerance in the multivariable
model (Table 2). The C value of the overall multivari-
able model was 0.83. Although the bootstrapped
model did degrade somewhat in performance, the C
value of 0.73 suggested moderate model performance.
DISCUSSION
NIV was prescribed to over half of ALS patients in
our clinic. Other investigations of NIV use have dem-
onstrated similar results, with 70 of 122 (57%)12
patients with FVC  50% being prescribed NIV. A
more recently published review of 92 U.S. and Ca-
nadian sites reported an NIV use prevalence of 33%
among ALS patients with FVC  50%.13 The same
study demonstrated that patients with lower incomes
and women were less likely to be prescribed NIV,
suggesting that these patients receive less aggressive
therapy.13 We did not find that women were less
likely to be tolerant to NIV, demonstrating that fe-
male gender does not negatively impact the success-
ful use of NIV.
NIV tolerance, assessed as nocturnal use 4 hours
per night, was achieved in 70% of our ALS patients.
This is much higher than the previously reported NIV
tolerance of 54%12 and 49%1 for ALS patients. As these
referenced comparison studies were performed prior
to publication of the practice parameters suggesting
survival benefit related to NIV use,17 our patients could
have been more motivated to use NIV than the patients
reported previously, as they may have been more aware
of the potential benefits. Practitioners may also have
been more motivated to encourage compliance and to
resolve NIV problems. A recent review of patients en-
rolled in the ALS CARE database from over 90 differ-
ent sites in North America compared disease manage-
ment before and after practice parameters were
published, and demonstrated a significant increase in
NIV use from 9% to 21% of database patients following
publication.5 However, 79% of patients in the ALS
CARE database with FVC  40%, thus meeting the
recommended prescribing criteria of both the Ameri-
can Academy of Neurology17 and American College of
Chest Physicians,3 were not using this treatment. Ap-
proximately half of this 79% were never offered NIV
and the other half either refused or could not tolerate
NIV treatment.5 In our clinic, education about NIV is
provided in person to the patients, supplemented by
phone contact as detailed earlier. We employ the tech-
niques described in the Methods section to promote
tolerance. Perhaps these measures improved NIV tol-
erability, although we suspect our management of NIV
intolerance is similar to that of other specialized ALS
clinics. Nonetheless, the high tolerance of NIV use
reported here underscores the opportunity for useful-
ness2,4,12 of NIV in ALS patients and should be consid-
ered when prescribing NIV.
We found that patients with limb-onset symptoms
were six times more likely to tolerate NIV than those
with bulbar-onset ALS. Our findings are in agreement
with two previous prospective studies.1,4 Both studies
also supported the association between bulbar symp-
toms and NIV intolerance, although these analyses did
not adjust for other clinical characteristics. Our results
do, however, contradict a previous retrospective analy-
sis.12 Bulbar-onset ALS patients are already known to
have a poorer prognosis than limb-onset patients at
diagnosis10,14 and are further disadvantaged by higher
intolerance to NIV. Further study into the reasons for
NIV intolerance in patients with prominent or early
bulbar symptoms may disclose ways to improve toler-
ance in this ALS subpopulation.
Table 2. Results of multivariable predictive model
for NIV tolerance.
OR 95% CI
Age 1.82 0.50, 6.58
FVC at NIV start 2.48 0.65, 9.45
Limb onset 6.25 1.09,33.33
Time from symptom to NIV start 1.15 0.50, 2.65
Female 4.32 0.74,25.19
Referent group for limb onset is bulbar onset. Referent group for female is
male. OR, odds ratio; CI, confidence interval; FVC, forced vital capacity
(percent predicted); NIV, noninvasive ventilation.
810 Short Reports MUSCLE & NERVE December 2005
Pulmonary function tests are used as a guide to
begin NIV in ALS patients and are assessed at routine
intervals per practice guidelines.17 Although not statis-
tically significant, we found a trend toward intolerance
in patients with a lower FVC at the time of NIV initia-
tion in the multivariable model, consistent with previ-
ous work.1,4 Although caution is required in interpret-
ing this finding, this trend is supportive of the
hypothesis that earlier administration of NIV, prior to
meeting standard-of-care criteria based on respiratory
muscle weakness, may increase NIV tolerance. This is
supported by Bourke et al., who described good NIV
tolerance in ALS patients with symptoms of orthopnea
despite average FVC  50%.4 Examination of the rela-
tionship between tolerance and FVC at the time of NIV
initiation in a larger data set may clarify this important
clinical issue.
FVC was 80% predicted within 3 months of
diagnosis in 70% of all ALS patients in this study.
In a cohort of 218 patients with motor neuron dis-
ease, Fallat et al. demonstrated that 106 patients
(49%) had FVC  80% at initial evaluation.7 In
contrast, we found that there was no difference be-
tween the percentage of bulbar-onset and limb-onset
ALS patients with FVC  80% within 3 months of
diagnosis. Although bulbar-onset patients have a
poorer prognosis and appear to be less tolerant to
NIV, they did not have a lower FVC at initial presen-
tation compared with limb-onset ALS patients.
The explanatory power of the statistical models
was limited by the small numbers in the data set.
Although the use of five clinical predictors in the
multivariable model may have resulted in overmod-
eling, we attempted to compensate for this by inter-
nally validating the model with bootstrapping. Boot-
strapping is a statistical technique that uses iterative
sampling with replacement to calculate a conserva-
tive estimate of model performance, estimating the
model’s discriminatory ability if applied to an out-
side data set.9 The results should nonetheless be
validated in an external data set. The use of subjec-
tive reporting of NIV tolerance, rather than objective
interrogation of NIV machines, and the retrospec-
tive nature of this study also represent limitations.
In conclusion, our findings indicate that a major-
ity of ALS patients administered NIV (70% in this
study) are tolerant of it. Assessment of predictors of
NIV tolerance only identified limb onset of ALS
symptoms as an independent predictor, although
higher FVC at NIV initiation may also be predictive
of NIV tolerance. Importantly, duration of disease
and age were not predictors of tolerability and
should not be considered reasons to withhold NIV.
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